AAPL   321.57 (-0.09%)
MSFT   183.36 (+0.29%)
FB   231.36 (-0.24%)
GOOGL   1,431.84 (-0.21%)
NVDA   348.51 (-1.06%)
BABA   208.86 (+1.11%)
MU   46.34 (+0.00%)
GE   7.00 (+3.55%)
AMD   53.41 (-0.41%)
T   30.88 (-0.16%)
ACB   14.30 (+1.42%)
GILD   74.07 (-1.45%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
BA   151.39 (+0.00%)
AAPL   321.57 (-0.09%)
MSFT   183.36 (+0.29%)
FB   231.36 (-0.24%)
GOOGL   1,431.84 (-0.21%)
NVDA   348.51 (-1.06%)
BABA   208.86 (+1.11%)
MU   46.34 (+0.00%)
GE   7.00 (+3.55%)
AMD   53.41 (-0.41%)
T   30.88 (-0.16%)
ACB   14.30 (+1.42%)
GILD   74.07 (-1.45%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
BA   151.39 (+0.00%)
AAPL   321.57 (-0.09%)
MSFT   183.36 (+0.29%)
FB   231.36 (-0.24%)
GOOGL   1,431.84 (-0.21%)
NVDA   348.51 (-1.06%)
BABA   208.86 (+1.11%)
MU   46.34 (+0.00%)
GE   7.00 (+3.55%)
AMD   53.41 (-0.41%)
T   30.88 (-0.16%)
ACB   14.30 (+1.42%)
GILD   74.07 (-1.45%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
BA   151.39 (+0.00%)
AAPL   321.57 (-0.09%)
MSFT   183.36 (+0.29%)
FB   231.36 (-0.24%)
GOOGL   1,431.84 (-0.21%)
NVDA   348.51 (-1.06%)
BABA   208.86 (+1.11%)
MU   46.34 (+0.00%)
GE   7.00 (+3.55%)
AMD   53.41 (-0.41%)
T   30.88 (-0.16%)
ACB   14.30 (+1.42%)
GILD   74.07 (-1.45%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
BA   151.39 (+0.00%)
Log in

NYSE:PKIPerkinElmer Stock Price, Forecast & News

$101.96
+1.49 (+1.48 %)
(As of 06/2/2020 09:27 AM ET)
Add
Compare
Today's Range
$99.96
Now: $101.96
$102.07
50-Day Range
$76.43
MA: $89.72
$100.47
52-Week Range
$62.91
Now: $101.96
$102.46
Volume628,977 shs
Average Volume962,025 shs
Market Capitalization$11.36 billion
P/E Ratio50.48
Dividend Yield0.28%
Beta1.37
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Read More
PerkinElmer logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.5Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.93 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
CUSIP71404610
Phone781-663-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.88 billion
Cash Flow$6.36 per share
Book Value$25.33 per share

Profitability

Net Income$227.56 million

Miscellaneous

Employees13,000
Market Cap$11.36 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

PerkinElmer (NYSE:PKI) Frequently Asked Questions

How has PerkinElmer's stock been impacted by COVID-19 (Coronavirus)?

PerkinElmer's stock was trading at $72.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PKI stock has increased by 40.0% and is now trading at $101.96. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PerkinElmer?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 10 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for PerkinElmer.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for PerkinElmer.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) announced its earnings results on Tuesday, May, 5th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.54 by $0.13. The medical research company earned $652.40 million during the quarter, compared to analysts' expectations of $634.46 million. PerkinElmer had a net margin of 7.82% and a return on equity of 16.52%. The company's revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter last year, the company posted $0.69 earnings per share. View PerkinElmer's earnings history.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, April 30th. Stockholders of record on Friday, July 17th will be paid a dividend of $0.07 per share on Friday, August 7th. This represents a $0.28 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Thursday, July 16th. View PerkinElmer's dividend history.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its second quarter earnings guidance on Tuesday, May, 5th. The company provided earnings per share (EPS) guidance of at least $0.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.59. The company issued revenue guidance of $610-720 million, compared to the consensus revenue estimate of $621.18 million.

What price target have analysts set for PKI?

15 equities research analysts have issued twelve-month price targets for PerkinElmer's shares. Their forecasts range from $49.00 to $114.00. On average, they anticipate PerkinElmer's stock price to reach $83.73 in the next twelve months. This suggests that the stock has a possible downside of 17.9%. View analysts' price targets for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

Press coverage about PKI stock has been trending very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. PerkinElmer earned a coverage optimism score of 3.5 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutPerkinElmer.

Are investors shorting PerkinElmer?

PerkinElmer saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,520,000 shares, a decline of 11.6% from the April 30th total of 2,850,000 shares. Based on an average daily trading volume, of 938,800 shares, the days-to-cover ratio is currently 2.7 days. Currently, 2.3% of the shares of the company are sold short. View PerkinElmer's Current Options Chain.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), NVIDIA (NVDA), IBM (IBM), Visa (V), Alibaba Group (BABA), Home Depot (HD), Johnson & Johnson (JNJ), Pfizer (PFE), Thermo Fisher Scientific (TMO) and Adobe (ADBE).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the following people:
  • Mr. Robert F. Friel, Chairman & CEO (Age 63)
  • Dr. Prahlad R. Singh, Pres & COO (Age 54)
  • Mr. James M. Mock, Sr. VP & CFO (Age 42)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)
  • Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56)

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a number of retail and institutional investors. Top institutional investors include Capital Research Global Investors (10.60%), BlackRock Inc. (6.42%), Janus Henderson Group PLC (5.83%), Massachusetts Financial Services Co. MA (4.39%), State Street Corp (4.04%) and King Luther Capital Management Corp (2.19%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View institutional ownership trends for PerkinElmer.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Primecap Management Co. CA, Pictet Asset Management Ltd., State of Michigan Retirement System, State of Michigan Retirement System, Sumitomo Mitsui Trust Holdings Inc., King Luther Capital Management Corp, and Massachusetts Financial Services Co. MA. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Pascale Witz, and Peter Barrett. View insider buying and selling activity for PerkinElmer.

Which institutional investors are buying PerkinElmer stock?

PKI stock was bought by a variety of institutional investors in the last quarter, including Echo Street Capital Management LLC, Alta Capital Management LLC, First Trust Advisors LP, Cannell Peter B & Co. Inc., Impax Asset Management Group plc, Robecosam AG, Swiss National Bank, and State Street Corp. View insider buying and selling activity for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $101.96.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $11.36 billion and generates $2.88 billion in revenue each year. The medical research company earns $227.56 million in net income (profit) each year or $4.10 on an earnings per share basis. PerkinElmer employs 13,000 workers across the globe.

What is PerkinElmer's official website?

The official website for PerkinElmer is www.perkinelmer.com.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.